GlassScriptPhysician profile
Bess L Chang
NPI 1942228515
$18,293.32
in general payments reported to CMS, 2019-2025
63 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,751 · 2020: $1,318 · 2021: $2,243 · 2022: $3,021 · 2023: $3,971 · 2024: $3,241 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,960.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,794.60 | 2021-2025 | Percept PC Brainsense |
| Abbott Laboratories | $1,457.34 | 2023-2025 | Infinity |
| Alexion Pharmaceuticals, INC. | $1,454.60 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $1,450.14 | 2020-2025 | Ingrezza, Ongentys |
| Medtronic USA, INC. | $1,290.22 | 2019-2020 | |
| Abbvie INC. | $1,280.98 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Merz Pharmaceuticals, LLC | $1,127.79 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Emd Serono, INC. | $871.86 | 2019-2024 | Mavenclad |
| Biogen, INC. | $702.55 | 2019-2023 | Tysabri, Vumerity |
| Nevro Corp. | $673.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $625.46 | 2019-2025 | |
| Genentech USA, INC. | $547.33 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Merz North America, INC. | $375.72 | 2019-2020 | |
| Ucb, INC. | $349.57 | 2019-2025 | Rystiggo |
| Sk Life Science, INC. | $338.38 | 2020-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bess Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.